Llwytho...
Natalizumab in Crohn’s Disease: Results from a US tertiary IBD center
BACKGROUND AND AIMS: Natalizumab is an efficacious agent for induction and maintenance of remission in Crohn’s disease (CD) patients who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center. M...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Inflamm Bowel Dis |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2013
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4779049/ https://ncbi.nlm.nih.gov/pubmed/23429449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0b013e31827eea78 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|